SCI
1November
AssociationofSurvivalWithAdjuvantChemotherapyAmongPatientsWithEarly-StageNon–SmallCellLungCancerWithvsWithoutHigh-RiskClinicopathologicFeatures
PathakR,GoldbergSB,CanavanM,etal.AssociationofSurvivalWithAdjuvantChemotherapyAmongPatientsWithEarly-StageNon–SmallCellLungCancerWithvsWithoutHigh-RiskClinicopathologicFeatures.JAMAOncol.PublishedonlineSeptember17,.doi:10./jamaoncol..
IMPORTANCE重要性
Tumorsizelargerthan4cmisacceptedasanindicationforadjuvantchemotherapyinpatientswithnode-negativenon–smallcelllungcancer(NSCLC).Treatmentguidelinessuggestthathigh-riskfeaturesarealsoassociatedwiththeefficacyofadjuvantchemotherapyamongpatientswithearly-stageNSCLC,yetthisassociationisunderstudied.
最大径大于4cm的肿瘤且淋巴结阴性的非小细胞肺癌（NSCLC）患者接受是术后接受辅助化疗的适应症。治疗指南表明，在具有高危因素的早期NSCLC患者的疗效也与辅助化疗相关，但这种关联尚未得到充分研究。
OBJECTIVE目的
Toassesstheassociationbetweenadjuvantchemotherapyandsurvivalinthepresenceandabsenceofhigh-riskpathologicfeaturesinpatientswithnode-negativeearly-stageNSCLC.
评估存在和不存在高危病理特征的淋巴结阴性早期NSCLC患者时辅助化疗与生存之间的关系。
DESIGN,SETTING,ANDPARTICIPANTS设计，设置和参与者
ThisretrospectivecohortstudyusingdatafromtheNationalCancerDatabaseincludedtreatment-naivepatientswitha
